Document is current
Any future updates will be listed below
-
Authors
Rwere, Freeborn
White, Joseph R.
Hell, Rafaela C. R.
Yu, Xuan
Zeng, Xiaocong
McNeil, Leslie
Zhou, Kevin N.
Angst, Martin S.
Chen, Che-Hong
Mochly-Rosen, Daria
Gross, Eric R. https://orcid.org/0000-0002-0589-6446
-
Funding
Funding for this research was provided by:
National Institute of General Medical Sciences (GM119522)
National Institute on Alcohol Abuse and Alcoholism (AA011147)
- License Information
-
More Information
Article History
Received: 2 February 2024
Accepted: 14 July 2024
First Online: 29 July 2024
Declarations
:
: All human studies were approved by the Institutional Review Board (IRB) at Stanford University (IRB 46095). Written informed consent was received from participants prior to inclusion in the study. The experiments conformed to the principles set out in the WMA Declaration of Helsinki and the Department of Health and Human Services Belmont Report.
: Not applicable.
: Eric Gross holds a patent related to the ALDH2 activator Alda-1, and is a consultant for Chiima Therapeutics. Daria Mochly-Rosen and Che-Hong Chen hold patents related to Alda-1. Dr. Angst has funding for a research study from Alkahest Inc. Additional authors have no disclosures.
